EUVIMEDEUVIMED entdecken
Crossref

Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Julia Belone Lopes iD, Ana Elisa Sanches iD, Beatriz de Menezes Dobbert iD, Lorena Forner, João Pedro Homse Netto iD, Luiza Fadul iD, João Daniel Guedes, Fábio Fernandez, Daniel Vilarim Araujo iD

JCO Global Oncology · 2025-08 · (11)

DOI: 10.1200/go-25-00132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025-08. Verfasst von Julia Belone Lopes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Abiraterone Acetate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Abiraterone acetate (AA) is approved for prostate cancer at a standard dose of 1,000 mg fasting. Because of a significant food effect, a lower dose (250 mg with food—AA low dose [AALD]) shows similar efficacy at 75% lower cost. In Brazil, 80% of patients rely on the public health care system, which does not cover the standard dose. Hospital de Base has been using AALD since March 2021. MATERIALS AND METHODS We retrospectively reviewed patients with metastatic castration-resistant prostate cancer (mCRPC) who received AALD at any treatment line, regardless of previous chemotherapy, between March 2021 and May 2023. The primary end point was prostate-specific antigen (PSA) response rate (RR; defined as a decrease of ≥50% in PSA level after 12 weeks of treatment). Secondary end points included time to treatment failure (TTF), overall survival (OS), and PSA RR ≥50% at nadir. RESULTS Ninety-six patients were included. Sixty-three patients (65.6%) received AALD in mCRPC first-line. After a median follow-up of 24.4 months, 53 patients (60.2%) achieved the primary end point, and 65 (69.9%) achieved a PSA reduction of ≥50% at nadir. Patients treated with AALD pre-docetaxel in the mCRPC had a higher PSA response at 12 weeks (68.3% v 40%, P = .015) and at nadir (76.1% v 53.8%, P = .036). First-line AALD was associated with better PSA responses. The median TTF was 7.9 months and the median OS was 20.6 months. Achieving a ≥50% PSA response at 12 weeks was associated with improved TTF (13.6 v 4.6 months, hazard ratio [HR] = 0.37, P < .001) and OS (28.9 v 12.2 months, HR = 0.44, P = .004). CONCLUSION AALD showed meaningful efficacy and survival outcomes. We support AALD use, especially where standard dosing is unaffordable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAbiraterone AcetateHumansMaleAgedRetrospective StudiesMiddle AgedProstate-Specific AntigenAged, 80 and overNeoplasm MetastasisAndrostenes

Substanzen

Prostate-Specific AntigenabirateroneAbiraterone AcetateAndrostenes

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil.
  • Division of Medical Oncology and Hematology, Department of Medicine, University of Florida, Gainesville, FL.

ORCID-Profile: Julia Belone Lopes, Ana Elisa Sanches, Beatriz de Menezes Dobbert, João Pedro Homse Netto, Luiza Fadul, Daniel Vilarim Araujo

Zitieren

APA

Lopes, J. B., Sanches, A. E., Dobbert, B. M., Forner, L., Homse Netto, J. P., Fadul, L., Guedes, J. D., Fernandez, F., & Araujo, D. V. (2025). Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer. JCO Global Oncology. https://doi.org/10.1200/go-25-00132

Vancouver

Lopes JB, Sanches AE, Dobbert BM, Forner L, Homse Netto JP, Fadul L, et al. Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer. JCO Global Oncology. 2025. doi:10.1200/go-25-00132

BibTeX
@article{Lopes2025,
  author = {Lopes, Julia Belone and Sanches, Ana Elisa and Dobbert, Beatriz de Menezes and Forner, Lorena and Homse Netto, João Pedro and Fadul, Luiza and Guedes, João Daniel and Fernandez, Fábio and Araujo, Daniel Vilarim},
  title = {Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer},
  journal = {JCO Global Oncology},
  year = {2025},
  number = {11},
  doi = {10.1200/go-25-00132}
}
Kostenlos starten →